StockWatch
·
DEEPAK NITRITE · Q2 FY-2027 · PREVIEW

Deepak Nitrite's Earnings Challenge: Can Growth Sustain After Record Q1?

Q1 FY27 delivered a stunning 207% profit surge and double-digit volume growth. Q2 faces the barre test: whether the margin expansion from fresh MIBK/MIBC capacity and phenol momentum can hold amid normal seasonal softness, or mark a one-off peak.

Q2 FY27 resultsDEEPAKNTRDEEPAK NITRITE LTD.-$23 Oct 2026 · 3 min read

What to Expect: Sustenance Over Records

Q1 FY27 was exceptional: consolidated revenue ₹2,577.6 Cr (+36% YoY), operating EBITDA ₹540.2 Cr (+185%), PAT ₹345 Cr (+207%), with EBITDA margin doubling to 20.96%. Both Phenolics and Advanced Intermediates hummed. Q2 enters a different context: April–June summer typically moderates specialty-chemical demand and export realizations, fresh capex ramps volume but not always at peak utilization or spread. Expect revenue to moderate sequentially to the ₹2,200–2,400 Cr range, with EBITDA margins normalizing to 17–19%—still robust, but 200bp down from Q1's extraordinary print.

Consolidated Revenue

~₹2,200–2,400 Cr

Sequential normalization from Q1's ₹2,577.6; YoY growth likely still double-digit

Operating EBITDA Margin

~17–19%

Down from Q1's 20.96%; reflects seasonal demand and production ramp leverage

PAT

~₹150–200 Cr

Normalized from Q1's exceptional ₹345 Cr; YoY growth trajectory to watch

Volume Trajectory

Ramp phase

MIBK/MIBC (₹735 Cr plant) and Chlor plant (₹300 Cr) just commissioned; expect modest Q2 build

A strong quarter would deliver ₹2,400+ Cr revenue with EBITDA margins holding at or above 18%, signaling that phenol and intermediate demand remain firm and capex ramps hold their utilization edge. A weak print would see revenue slip below ₹2,200 Cr or margins compress below 16%, indicating that the bounce was concentrated in a single spike or that oversupply / export pressure has returned sooner than expected.

On Track? The Capex Execution Playbook

Deepak Nitrite has signaled FY27 margins will surpass FY26, driven by capacity ramps and product mix. The evidence is credible: in August–September, it commissioned a ₹735 Cr MIBK/MIBC facility, a ₹300 Cr chlorination plant, and cleared a ₹2,500 Cr BPA investment. This capex cadence—moving from approval to commercial operation inside 12 months—demonstrates execution rigor. Q2 is still in the ramp phase; don't expect full-plant margin contribution yet. But if volumes and spreads hold, the full-year guide (margins up YoY) becomes credible. Watch for evidence on the earnings call: utilization rates on new plants, customer offtake, any pricing pressure.

What the Street Says

Since Last Quarter: Capex Milestones and Guidance Anchors

Recent Filings & Events
  • 1 · Capex Commissioning (Aug–Sep 2026)

    MIBK/MIBC plant (₹735 Cr) and Chlorination plant (₹300 Cr) both now operational. Subsidiary DCTL invested ₹80 Cr in new OCRPS to fund ops. Volume ramp expected Q2–Q3; margin contribution marginal until utilization > 50%.

  • 2 · BPA Investment Approved (Aug 2026)

    DCTL Board cleared ₹2,500 Cr capex for 240 KTA Bisphenol A facility. This is a 3–4 year build (est. FY28–FY29 commercial), not material to Q2 or FY27 earnings but signals long-term growth playbook.

  • 3 · Subsidiary Debt Guarantee (Jul 2026)

    Deepak Nitrite guaranteed a $78.43M term loan for subsidiary DOIL (Oman Ops). Routine capex financing; no operational impact on Q2.

  • 4 · Management Change (Aug 2026)

    SBU Head of Life Sciences resigned; board composition updated. Minor change; no material operational signal.

  • 5 · Trading Window Closure (Sep 2026)

    Standard insider trading blackout for results publication. No unusual director buying/selling pre-announcement.

The Setup

Deepak Nitrite's Q2 FY27 story hinges on two moves: (1) whether the 207% profit surge in Q1 was a sustainable step-up or a seasonal spike, and (2) whether fresh capex (MIBK/MIBC, Chlorination) can reach 60%+ utilization and maintain margin profile into Q3–Q4. The Street is cautiously optimistic (Hold, 24% upside), but execution on volume ramp and spot spreads will define the narrative. Valuation at 25–26x FY27E EPS leaves no room for miss.

Three Things to Watch on Result Day (Oct 30)

Key Metrics & Management Guidance
  • 1 · EBITDA Margin Trajectory

    If Q2 EBITDA margin ≥ 18%, it signals Q1 was not a peak but a new run-rate level. Below 16% would suggest mean reversion. Listen to mgmt commentary on pricing pressure (export realizations, domestic competition) and utilization.

  • 2 · Capex Utilization Update

    CFO should quantify production from the MIBK/MIBC and Chlorination plants: volume shipped, realized pricing vs guidance, path to 75%+ utilization. This is the execution metric investors care about most.

  • 3 · FY27 Guidance Reiteration

    Will mgmt reaffirm that FY27 margins will exceed FY26? If guidance is raised or lowered in light of Q2 print, it resets Street expectations. Watch for any commentary on FY28 (BPA plant impact timeline, polycarbonate facility progress).

Deepak Nitrite reports Q2 FY27 results on October 29, 2026 (Board meeting), with a management earnings call on October 30 at 3:30 PM IST. The stock trades at ₹1,487.4, down 53% from its ATH but up 16% from its 52-week low. Street consensus is Hold with a ₹1,852 target, premised on sustained margin expansion from capex ramps. Q2 is the test: can it deliver 17%+ EBITDA margin and show credible volume ramp in new plants? Or does it normalize back toward 14–15%, signaling that Q1 was a seasonal spike? The answer will anchor Street expectations through H2 FY27.

Informational and educational content only. Not investment advice.